Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome
Background/Aims In this study, we tested whether mutations in the methylation pathway genes ten-eleven-translocation 2 (TET2) and DNA methyltransferase gene 3A (DNMT3A) improve the responses of patients with myelodysplastic syndrome (MDS) to decitabine. Methods We retrospectively sequenced the TET2...
Main Authors: | Hyun Ae Jung, Chul Won Jung, Jun Ho Jang |
---|---|
Format: | Article |
Language: | English |
Published: |
The Korean Association of Internal Medicine
2021-03-01
|
Series: | The Korean Journal of Internal Medicine |
Subjects: | |
Online Access: | http://www.kjim.org/upload/pdf/kjim-2019-385.pdf |
Similar Items
-
Effective treatment of low-dose decitabine in myelodysplastic syndrome/myeloproliferative neoplasms
by: Ye X, et al.
Published: (2017-11-01) -
Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes
by: V N Dvirnyk, et al.
Published: (2013-07-01) -
Decitabine Induces Change of Biological Traits in Myelodysplastic Syndromes via FOXO1 Activation
by: Zheng Zhang, et al.
Published: (2021-01-01) -
A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
by: Jehad Almasri, et al.
Published: (2018-09-01) -
DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers
by: Ana Cristina Gonçalves, et al.
Published: (2021-06-01)